Meeting
2023 ASCO Annual Meeting
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy.
Authors
David S. Hong
University of Texas MD Anderson Cancer Center, Houston, TX
David S. Hong , Yasutoshi Kuboki , John H Strickler , Marwan Fakih , Hélène Houssiau , Timothy Jay Price , Elena Elez , Salvatore Siena , Emily Chan , Jane Nolte-Hippenmeyer , Panli Cardona , Qui Tran , Toshiki Masuishi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04185883
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3513)
DOI
10.1200/JCO.2023.41.16_suppl.3513
Abstract #
3513
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Evaluation of SN-38 PK profile in patients with RAS wild-type metastatic colorectal cancer treated with a combination of SCO-101 and FOLFIRI.
First Author: Jakob Hagen Vasehus Schou
Poster
2020 Gastrointestinal Cancers Symposium
Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.
First Author: Thomas H. Cartwright
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
First Author: Kaori Hayashi